Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Y Lin

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Cell Chemical Biology|March 19, 2019
Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven TranscriptionNicholas B Struntz, Andrew Chen, Anja Deutzmann, et al.
Cancer Discovery|August 28, 2024
MYC Induces Oncogenic Stress through RNA Decay and Ribonucleotide Catabolism in Breast CancerJitendra K Meena, Jarey H Wang, Nicholas J Neill, et al.
Nature Communications|September 27, 2019
High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC programDavid P Labbé, Giorgia Zadra, Meng Yang, et al.
Nature Medicine|March 27, 2018
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancerAmritha Nair, Hsiang-Ching Chung, Tingting Sun, et al.
Nature|January 28, 2016
Active medulloblastoma enhancers reveal subgroup-specific cellular originsCharles Y Lin, Serap Erkek, Yiai Tong, et al.
Nature Chemical Biology|April 7, 2020
Discovery of a selective inhibitor of doublecortin like kinase 1Fleur M Ferguson, Behnam Nabet, Srivatsan Raghavan, et al.
Cell|January 15, 2021
Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancerElizabeth A Bowling, Jarey H Wang, Fade Gong, et al.
Nature|January 7, 2016
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancerShaokun Shu, Charles Y Lin, Housheng Hansen He, et al.
Cell Chemical Biology|October 21, 2020
Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 InhibitorsAndré Richters, Shelby K Doyle, David B Freeman, et al.
The Journal of Clinical Investigation|October 5, 2020
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastomaEvon Poon, Tong Liang, Yann Jamin, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Cell Chemical Biology|March 19, 2019
Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven TranscriptionNicholas B Struntz, Andrew Chen, Anja Deutzmann, et al.
Cancer Discovery|August 28, 2024
MYC Induces Oncogenic Stress through RNA Decay and Ribonucleotide Catabolism in Breast CancerJitendra K Meena, Jarey H Wang, Nicholas J Neill, et al.
Nature Communications|September 27, 2019
High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC programDavid P Labbé, Giorgia Zadra, Meng Yang, et al.
Nature Medicine|March 27, 2018
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancerAmritha Nair, Hsiang-Ching Chung, Tingting Sun, et al.
Nature|January 28, 2016
Active medulloblastoma enhancers reveal subgroup-specific cellular originsCharles Y Lin, Serap Erkek, Yiai Tong, et al.
Nature Chemical Biology|April 7, 2020
Discovery of a selective inhibitor of doublecortin like kinase 1Fleur M Ferguson, Behnam Nabet, Srivatsan Raghavan, et al.
Cell|January 15, 2021
Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancerElizabeth A Bowling, Jarey H Wang, Fade Gong, et al.
Nature|January 7, 2016
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancerShaokun Shu, Charles Y Lin, Housheng Hansen He, et al.
Cell Chemical Biology|October 21, 2020
Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 InhibitorsAndré Richters, Shelby K Doyle, David B Freeman, et al.
The Journal of Clinical Investigation|October 5, 2020
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastomaEvon Poon, Tong Liang, Yann Jamin, et al.
Pageof 9